Research and Markets: DRG Insights: CV Overview (G7)

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/vd32l3/drg_insights_cv) has announced the addition of Decision Resources, Inc's new report "DRG Insights: CV Overview (G7)" to their offering.

DRG Insights takes the most relevant information and insights from across our portfolio for BioPharma and Med-Tech products and delivers the insight heavy perspective that you need to generate better ideas and deliver more successful campaigns and initiatives. With sales growth of 1.6% year-on-year (YoY), 2011 was a modest period for the Cardiovasculars sector.

This result reflects the fact that the two largest cardiovascular drug classes (the AIIRAs and Statins), with 2011 annual sales of $23.8b and $21.8b, respectively, have reached maturity. Throughout the forecast period, both of these key drug classes will endure sustained losses as a result of aggressive generic erosion that will set in from 2011 onwards (concomitant with the loss of patent protection for Pfizer's Lipitor and Novartis' Diovan).

Key Topics Covered:

Market Overview

Epidemiology & Unmet Needs

Treatment Algorithms

Current Therapies

Current/Projected Market Share

Emerging Therapies

Drug Sales & Forecasts for each of the following CVD Indications: Acute Coronary Syndrome (UA/NSTEMI/NSTE-ACS)

Arrhythmias (AF Ventricular)

Heart Failure (acute/chronic)

Hypertension

Lipid Disorders (hyperlipidemia/dyslipidemia)

Peripheral Arterial Disease

Pulmonary Arterial Hypertension

Stroke (Ischemic/Hemmorhagic)

Thrombosis (Venous/Arterial)

For more information visit http://www.researchandmarkets.com/research/vd32l3/drg_insights_cv

Source: Decision Resources, Inc

Research and Markets
Laura Wood, Senior Manager.
[e-mail]
U.S. Fax: [phone]
Fax (outside U.S.): [phone]
Sector: Healthcare and Medical Devices, Pharmaceuticals

Source: Research and Markets